Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Gene Therapy as Treatment for Purine Nucleoside Phosphorylase Primary Immune Deficiency

EF 2020-21

Résumé
Patients born with purine nucleoside phosphorylase (PNP) deficiencies suffer from recurrent infections, autoimmunity, and cognitive and developmental delays since infancy. Many of the symptoms and complications that arise from the weakened immune system in PNP deficiency can be mitigated with early diagnosis, in addition to the use of antibiotics preventatively and therapeutically, protein replacement and immune suppression medications. However, these therapies require life-long adherence to medication schedules, and are often associated with significant burdens on the patient's quality-of-life, their families and society. Currently, the only option for long-term correction of the immune abnormalities for these patients is a stem cell transplant from a healthy matched patient. This option, however, is not available for most patients while using unmatched or parent donors is associated with higher chances of complications and death from the immune reaction of the donor cells against the patient recipient following the transplant. To combat these challenges, we have produced a virus that can deliver the corrected PNP gene into the patient's cells that will be used to repair the deficiency in human patients. We will ensure that the virus is both effective in its ability to reconstitute activity of the missing or non-functional enzyme, and that it is safe for use in patients. This novel gene therapy will provide a one-time, safe and effective long-term solution for these patients thereby significantly enhancing the quality-of-life for these individuals.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449530
Name
Loves Robyn
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Gene Therapy as Treatment for Purine Nucleoside Phosphorylase Primary Immune Deficiency
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Gene Therapy; Hematology; Immunology; Metabolic Disorder; Pediatrics; Primary Immune Deficiency; Rare Diseases; Stem Cell Transplant; Stem Cells; Viral Vector
Abstract
Patients born with purine nucleoside phosphorylase (PNP) deficiencies suffer from recurrent infections, autoimmunity, and cognitive and developmental delays since infancy. Many of the symptoms and complications that arise from the weakened immune system in PNP deficiency can be mitigated with early diagnosis, in addition to the use of antibiotics preventatively and therapeutically, protein replacement and immune suppression medications. However, these therapies require life-long adherence to medication schedules, and are often associated with significant burdens on the patient's quality-of-life, their families and society. Currently, the only option for long-term correction of the immune abnormalities for these patients is a stem cell transplant from a healthy matched patient. This option, however, is not available for most patients while using unmatched or parent donors is associated with higher chances of complications and death from the immune reaction of the donor cells against the patient recipient following the transplant. To combat these challenges, we have produced a virus that can deliver the corrected PNP gene into the patient's cells that will be used to repair the deficiency in human patients. We will ensure that the virus is both effective in its ability to reconstitute activity of the missing or non-functional enzyme, and that it is safe for use in patients. This novel gene therapy will provide a one-time, safe and effective long-term solution for these patients thereby significantly enhancing the quality-of-life for these individuals.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Loves, Robyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~